FCE
Fiera Capital (Europe) Portfolio holdings
AUM $213M
1-Year Return
42.4%
This Quarter Return
-0.67%
1 Year Return
+42.4%
3 Year Return
+41.22%
5 Year Return
–
10 Year Return
–
AUM
$139M
AUM Growth
+$12.8M
(+10%)
Cap. Flow
+$13.4M
Cap. Flow
% of AUM
9.7%
Top 10 Holdings %
Top 10 Hldgs %
75.13%
Holding
63
New
6
Increased
17
Reduced
13
Closed
4
Top Buys
| 1 |
Petrobras Class A
PBR.A
|
+$8.73M |
| 2 |
CBD
Companhia Brasileira de Distribuicao
CBD
|
+$3.83M |
| 3 |
Grupo Aval
AVAL
|
+$3.78M |
| 4 |
VNET
VNET Group
VNET
|
+$3.17M |
| 5 |
JD.com
JD
|
+$1.71M |
Top Sells
| 1 |
New Oriental
EDU
|
+$6M |
| 2 |
Baidu
BIDU
|
+$2.58M |
| 3 |
Credicorp
BAP
|
+$2.55M |
| 4 |
Ambev
ABEV
|
+$1.44M |
| 5 |
Vale
VALE
|
+$848K |
Sector Composition
| 1 | Financials | 24.5% |
| 2 | Communication Services | 20.4% |
| 3 | Consumer Staples | 17.41% |
| 4 | Energy | 15.31% |
| 5 | Consumer Discretionary | 4.23% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
26
Gilead Sciences
GILD
$139B
| $428K | 0.31% |
4,020
+1,110
| +38% | +$118K |
|
27
AbbVie
ABBV
$390B
| $309K | 0.22% |
5,332
| – | – |
|
28
Thermo Fisher Scientific
TMO
$180B
| $247K | 0.18% |
2,020
+398
| +25% | +$48.7K |
|
29
Viatris
VTRS
$11.3B
| $234K | 0.17% |
5,115
+1,035
| +25% | +$47.3K |
|
30
Bristol-Myers Squibb
BMY
$94.9B
| $227K | 0.16% |
4,427
| – | – |
|
|
MDVN
31
DELISTED
MEDIVATION, INC.
MDVN
| $227K | 0.16% |
4,588
| – | – |
|
32
Abbott
ABT
$232B
| $213K | 0.15% |
5,110
+2,255
| +79% | +$94K |
|
|
SLXP
33
DELISTED
SALIX PHARMACEUTICALS LTD DEL
SLXP
| $188K | 0.14% |
1,197
+516
| +76% | +$81K |
|
34
Insulet
PODD
$22.7B
| $180K | 0.13% |
4,868
| – | – |
|
35
Medtronic
MDT
$121B
| $169K | 0.12% |
2,718
| – | – |
|
|
CELG
36
DELISTED
Celgene Corp
CELG
| $167K | 0.12% |
1,756
+1,060
| +152% | +$101K |
|
37
Illumina
ILMN
$15.5B
| $156K | 0.11% |
975
+274
| +39% | +$43.8K |
|
38
Sanofi
SNY
$115B
| $152K | 0.11% |
2,700
| – | – |
|
|
OREX
39
DELISTED
Orexigen Therapeutics, Inc.
OREX
| $150K | 0.11% |
3,520
| – | – |
|
40
Becton Dickinson
BDX
$54.1B
| $120K | 0.09% |
1,076
| – | – |
|
|
PCYC
41
DELISTED
PHARMACYCLICS INC
PCYC
| $110K | 0.08% |
937
| – | – |
|
42
Theravance Biopharma
TBPH
$702M
| $101K | 0.07% |
4,340
| – | – |
|
43
Amgen
AMGN
$148B
| $95K | 0.07% |
675
-390
| -37% | -$54.9K |
|
|
NPSP
44
DELISTED
NPS PHARMACEUTICALS INC
NPSP
| $88K | 0.06% |
3,346
+1,470
| +78% | +$38.7K |
|
45
Stryker
SYK
$144B
| $85K | 0.06% |
1,047
+565
| +117% | +$45.9K |
|
46
Biogen
BIIB
$21.2B
| $78K | 0.06% |
236
| – | – |
|
47
Innoviva
INVA
$1.23B
| $78K | 0.06% |
4,532
| – | – |
|
|
IPXL
48
DELISTED
Impax Laboratories, Inc.
IPXL
| $68K | 0.05% |
2,865
| – | – |
|
49
IQVIA
IQV
$32.1B
| $54K | 0.04% |
973
| – | – |
|
50
BioMarin Pharmaceuticals
BMRN
$10.5B
| $48K | 0.03% |
664
| – | – |
|